Welcome to our dedicated page for Mustgrow Biologics news (Ticker: MGROF), a resource for investors and traders seeking the latest updates and insights on Mustgrow Biologics stock.
MustGrow Biologics Corp. reports developments in biological and regenerative agriculture, including mustard-derived biofertility, biostimulant and biocontrol products. News commonly covers commercialization of TerraSante in U.S. agricultural markets, field work for TerraMG in soil-borne disease suppression, and crop nutrition sales through the NexusBioAg Canadian distribution platform.
Company updates also address annual and quarterly financial results, capital raises, inventory and working-capital funding, organic product registrations, patent portfolio activity, and collaborations with agriculture companies outside North America.
MustGrow Biologics (MGROF) appointed Tyler Reinheimer, CPA, as Director, Finance and granted a total of 1,126,954 deferred share units (DSUs) to certain directors and Mr. Reinheimer, effective September 3, 2026.
The DSUs, issued under the omnibus equity incentive plan, vest when the holder leaves their role, and each DSU can be settled in one common share or an equivalent cash payment at the Company’s discretion.
MustGrow Biologics (OTCQB: MGROF) reported Q2 2026 results for the period ended June 30, 2026. TerraSanteTM sales were $75,000, down from $313,000 in Q2 2025, with gross margin effectively nil due to costly air freight used to ensure timely delivery. A licensing revenue milestone of $1.4 million was recognized in the quarter. Expenses from continuing operations were $0.9 million, flat year over year, resulting in net profit from continuing operations of $0.4 million versus a $0.9 million loss in Q2 2025. Cash and equivalents were $4.4 million and working capital was $5.2 million at June 30, 2026. As of August 15, 2026, year-to-date TerraSanteTM sales reached $0.9 million, more than 46% above all TerraSanteTM sales in full-year 2025. MustGrow also entered a 12‑month market awareness and investor relations agreement with Apaton Finance with a EUR 120,000 budget.
MustGrow Biologics (OTCQB: MGROF) announced receipt of the first development milestone payment from Bayer AG under their December 2023 License and Collaboration Agreement for mustard-based biocontrol soil applications in Europe, the Middle East and Africa.
Bayer is responsible for formulation, regulatory studies, submissions, registrations and commercialization activities in the territory. MustGrow estimates that the combined value of upfront and potential milestone payments plus Bayer-funded development work could total approximately US$35–40 million over the next 5–7 years, with minimal incremental costs to MustGrow aside from supplying product for testing.
MustGrow Biologics (OTCQB:MGROF) released results of its June 25, 2026 annual shareholder meeting.
All nominated directors were elected, generally receiving about 99.7% of votes cast. Shareholders also re-appointed Ernst & Young LLP as auditors and approved an amended omnibus equity incentive plan, which still requires final TSX Venture Exchange approval.
MustGrow Biologics (OTCQB: MGROF) reported Q1 2026 results for the period ended March 31, 2026.
- TerraSante revenue of $0.1 million vs. nil in Q1 2025
- TerraSante gross margin 23.6% vs. 19.5% in 2025
- Expenses from continuing operations $0.9 million vs. $1.2 million
- Net loss $1.3 million vs. $1.6 million
- Cash $0.4 million; working capital $1.5 million
MustGrow highlighted TerraSante contract manufacturers transitioning from batch to continuous production, causing short-term manufacturing disruptions in Q1 and into Q2 while increasing long-term capacity.
MustGrow (OTCQB: MGROF) received agriculture department registrations in Texas, Utah, and Montana, allowing sales of its mustard-derived organic biofertility product TerraSante(TM). These approvals extend TerraSante's availability to 10 U.S. states under Organic OMRI Listed® certification and California's OIM Program.
According to MustGrow, infield grower data indicate TerraSante may improve crop yields, soil health, and nutrient and water use efficiencies by feeding soil microbes with plant proteins and carbohydrates, with no artificial additives or preservatives used in manufacturing.
MustGrow Biologics (OTCQB:MGROF) announced new market awareness and investor relations agreements aimed at increasing visibility, in line with TSX Venture Exchange disclosure rules.
The company engaged Market One Media Group for 12 months for $70,000 and GBC AG for 24 months at EUR 40,000 per year to reach German and European investors.
MustGrow (OTCQB: MGROF) reported audited 2025 results: sales $8.3M (2024: $0.4M), expenses $7.7M (2024: $5.4M) and a net loss $7.3M (2024: $4.9M). TerraSante U.S. sales were $0.6M (+377%) with a 20% gross margin. Cash was $0.9M and inventory $2.0M as of Dec 31, 2025. The company raised $2M in January 2026 and closed its NexusBioAg Canadian distribution division in April 2026 to focus on U.S. TerraSante growth and scaled contract manufacturing.
MustGrow (OTCQB: MGROF) received Georgia Department of Agriculture registration to sell TerraSante™, its mustard-derived organic biofertility product, expanding state approvals to include Georgia alongside California, Florida, Arizona, Idaho, Oregon, and Washington.
The Georgia registration adds organic OMRI-listed certification coverage and targets high-value Georgia crop acres where TerraSante™ is positioned to be marketed.
MustGrow (TSXV: MGRO / OTCQB: MGROF) announced results from a 2-year, ~100-acre Prairie field program showing its mustard-derived biocontrol TerraMG reduced Clubroot inoculum and improved canola root health and yields. Trials showed up to 95% spore reductions in 2024 and yield gains up to 7 bu/acre (≈19%). The company is pursuing registration with Health Canada's Pest Management Regulatory Agency and reports variable 2025 gains (1–2 bu/acre) in drier, lower-disease conditions.